Agilent Technologies (NYSE: A), a global leader in life sciences, diagnostics, and applied chemical markets, has announced a strategic collaboration with Shanghai Majorbio Bio-pharm Technology Co., Ltd, a prominent biopharmaceutical company in China. This partnership will provide Majorbio with access to Agilent’s cutting-edge sample quality control solutions and its flagship SureSelect product, which is pivotal for human whole exome targeted sequencing.
Majorbio, now recognized as an ‘Agilent Sample Quality Control Certification Laboratory’, will work closely with Agilent to offer a suite of high-quality, one-stop scientific and technological services tailored to the life science research sector in China. This alliance aims to enhance research capabilities and accelerate scientific discoveries within the region.
The collaboration will also focus on the development of innovative whole exome sequencing products. Based on Agilent’s SureSelect Human All Exon V8, these products will leverage Majorbio’s expertise to provide comprehensive genomic analysis solutions. This technology is expected to play a significant role in advancing personalized medicine and enhancing diagnostic accuracy.
This strategic partnership is a testament to Agilent’s commitment to driving innovation in life sciences and diagnostics. By joining forces with Majorbio, Agilent is poised to make a substantial impact on the life science research landscape in China, contributing to the global advancement of scientific research and healthcare solutions.- Flcube.com
